Seres Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Seres Therapeutics

08/05/2024 14:17

* Seres Therapeutics Inc  MCRB.OQ  reported a quarterly
adjusted
loss of 27 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -57 cents.  The mean expectation of six analysts
for the quarter was for a loss of 34 cents per share. Wall
Street expected results to range from -43 cents to -26 cents per
share.
    * Reported revenue was zero​; analysts expected $250.00
thousand. 
    * Seres Therapeutics Inc's reported EPS for the quarter was
a loss
of 27 cents​.
    * The company reported a quarterly loss of $40.13 million.
    * Seres Therapeutics Inc shares had risen by 43.4% this
quarter and lost 20.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Seres
Therapeutics Inc is $7.00 
This summary was machine generated from LSEG data May 8 at 01:17
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.34          -0.27          Beat
 Dec. 31 2023      -0.50          -0.32          Beat
 Sep. 30 2023      -0.50          -0.37          Beat
 Jun. 30 2023      0.53           0.36           Missed